Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.
Pascal Richard David ClephasVictor W ZwartkruisJishnu MalgieMarco W F van GentHans-Peter Brunner-La RoccaMariusz K SzymanskiVokko P van HalmM Louis HandokoWouter E M KokFolkert W. AsselbergsRoland R J van KimmenadeOlivier C ManintveldNicolas M D A van MieghemSaskia Lambertha Maria Anna BeeresMarco C PostC Jan Willem BorleffsRaymond TukkieArend MosterdGerard C M LinssenRuud F SpeeMireille E EmansTom D J SmildeJan van RamshorstCharles J H J KirchhofMargriet W Feenema-AardemaCarlos A da FonsecaMieke van den HeuvelRonald HazelegerMartijn van EckLoek van HeerebeekEric BoersmaMichiel RienstraRudolf A de BoerJasper J BrugtsPublished in: European heart journal (2024)
This subgroup analysis confirmed the consistent benefits of PA-guided HF therapy observed in the MONITOR-HF trial across clinically relevant subgroups, highlighting its efficacy in improving quality of life, clinical, and PA pressure endpoints in chronic HF patients.
Keyphrases
- pulmonary artery
- ejection fraction
- phase iii
- end stage renal disease
- acute heart failure
- coronary artery
- pulmonary hypertension
- study protocol
- pulmonary arterial hypertension
- clinical trial
- chronic kidney disease
- newly diagnosed
- phase ii
- peritoneal dialysis
- heart failure
- prognostic factors
- randomized controlled trial
- open label
- atrial fibrillation
- patient reported outcomes
- cell therapy
- patient reported
- smoking cessation
- replacement therapy